Arctic Bioscience Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Christer Valderhaug

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	0.06%
Durée moyenne d'occupation des postes de direction	6.2yrs
Durée moyenne du mandat des membres du conseil d'administration	5.1yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Christer Valderhaug (52 yo)

no data

Titularisation

Mr. Christer L. Valderhaug serves as Chief Executive Officer at Arctic Bioscience AS. He serves as Senior Advisor at Converto Holding As (formerly known as Converto AS) since November 2016. He came from th...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Harald Nordal	Co-Founder & Chairman	9.1yrs	pas de données	0.079% € 3.5k
Christer Valderhaug	Chief Executive Officer	no data	pas de données	0.055% € 2.4k
Hogne Hallaraker	Founder & Chief Scientific Officer	6.6yrs	pas de données	1.83% € 80.6k
Jone Slinning	Chief Financial Officer	2.6yrs	pas de données	0.052% € 2.3k
Per Sæbo	Chief Operating Officer	12.3yrs	pas de données	0.090% € 4.0k
Daniele Mancinelli	Chief Technical Officer	12.3yrs	pas de données	0.0079% € 346.7
Steffen Eidal	Senior Vice President of Sales & Marketing	2.6yrs	pas de données	pas de données
Yuming Feng	Executive Vice President of Global Business Development	6.2yrs	pas de données	pas de données
Runhild Gammelsæter	Global Medical Director	5.3yrs	pas de données	0.14% € 6.0k

6.2yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de 9TD est chevronnée et expérimentée (6.2 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Harald Nordal	Co-Founder & Chairman	9.1yrs	pas de données	0.079% € 3.5k
Jostein Dalland	Independent Board Member	4.7yrs	pas de données	pas de données
Tore Andreas Tonseth	Board Member	3.8yrs	pas de données	pas de données
Asbjorn Solevagseide	Board Member	5.6yrs	pas de données	pas de données
Jan Vartdal	Board Member	9.1yrs	pas de données	4.1% € 180.4k
Per Eggesbo	Board Member	8.8yrs	pas de données	pas de données
Hu Cao	Board Member	3.8yrs	pas de données	pas de données
Marita Holstad	Director	3.8yrs	pas de données	pas de données

5.1yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 9TD sont considérés comme expérimentés (ancienneté moyenne 5.1 ans).

Arctic Bioscience Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Recent updates

Arctic Bioscience AS Provides Revenue Guidance for the Year 2024

New major risk - Market cap size

Arctic Bioscience Announces Top-Line Results from Phase 2b HeROPA Study

New major risk - Financial position

Arctic Bioscience Announces New Positive Data Showing Anti-Inflammatory Effects of Phospholipid Esters from Herring Roe in Immune Cells

Full year 2023 earnings released: kr1.79 loss per share (vs kr1.39 loss in FY 2022)

Full year 2023 earnings released

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

New major risk - Revenue and earnings growth

Arctic Bioscience Announces Recruitment Completed in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS to Report Fiscal Year 2023 Results on Apr 09, 2024

Arctic Bioscience Announces More Than 75% Recruitment in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

New minor risk - Financial data availability

Arctic Bioscience AS Provides Earnings Guidance for the Year 2023

Arctic Bioscience as Announces Operational Update - Heropa Clinical Trial Approved in All 5 Countries and Ongoing

Full year 2022 earnings released

Global Medical Director recently bought €15k worth of stock

Chief Executive Officer recently bought €28k worth of stock

Arctic Bioscience AS (OB:ABS) acquired Arctic Algae As from Ronja Capital II AS for enterprise value NOK 16.3 million.

Arctic Bioscience Announces First Patient Included in HRO350 Phase IIb Clinical Trial in the UK

Arctic Bioscience Announces Clinical Trial Application for HRO350 Phase IIb Approves in UK

Arctic Bioscience AS to Report Fiscal Year 2022 Results on Mar 29, 2023

Less than half of directors are independent

Arctic Bioscience as Maintains Earnings Guidance for the Year 2022

Arctic Bioscience Submits Clinical Trial Application for Hro350 Phase IIb

Arctic Bioscience AS Announces Update on Clinical Trial Application for HRO350 Phase IIb

Arctic Bioscience as Provides Revenue Guidance for the Year 2022

Less than half of directors are independent

Full year 2021 earnings released

Arctic Bioscience Provides Earnings Guidance for the Fiscal Year 2022

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Arctic Bioscience AS Provides Earnings Guidance for the Year 2021

Arctic Bioscience Receives Grant from the Research Council of Norway for Its Pharmaceutical Development

Arctic Bioscience Provides Financial Guidance for the Fiscal Year 2021

Arctic Bioscience Signs 3-Year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen